Boston, MA 10/06/2014 (wallstreetpr) – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) revealed in a declarative statement that the prestigious National Institute of Allergy and Infectious Diseases, dubbed as NIAID, has aptly practiced two options that provides manufacture of the product – BCX4430 and another GMP drug substance. If these options are duly exercised, it would lead to a whopping increase in the current development contract deal by another $2 million!
Earning Profits Is Easier With BioCryst
The recent news caught the eye of a plenitude of investors and led to sumptuous share transactions. In general, the average trade volume staggers at around 1.06 million shares in a day. This shot up to almost 7.51 million on Friday, after the declarative statement. BCRX’s share price surged up by a whopping margin of 12.43%, settling at $12.80 per share at the close of the day’s trade on Friday. The current market capitalization for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is $8.6.95 million. A net number of 71.76 million shares are outstanding, awaiting purchases!
Market Responses
The markets in the Europe and the US are taking shape to bolster the net return on investments! The European market is witnessing a series of stimulus efforts that effect in propping up growth. The US, is however upbeat in halting the varied monthly programs pertaining to buying available bonds in October. The end of quantitative easing, has been marked by high rates of interests that depicts options for better growth.
Ebola Scare Shoots Share Price Higher
Meanwhile, the rise in Ebola scare across the globe led to shooting up of share prices of quite a few of the pharmaceutical companies who are capable and competent in manufacturing drugs to tackle and obviate the Ebola scare.
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and BCRX garnered the maximal gains, since they are associated with research work and manufacturing of potential drugs and vaccines to tackle the Ebola havoc and fear abound.
Early Projections
With the predictions from the Centers for Disease Control (CDC) projecting that approximately 1.4 million individuals in the West African nations shall be victimized by the deadly Ebola by January 2015, the investors have banked upon various pharma companies like BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and have purchased their shares, hoping that these companies would do good in finding ways to tackle the Ebola scare.
